Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

NIH halts COVID-19 convalescent plasma trial, renewing calls for FDA to withdraw authorization

More than 100,000 Americans have been treated despite lack of evidence showing efficacy 

March 3, 2021 2:21 AM UTC

NIH announced Tuesday that it has halted a trial of COVID-19 convalescent plasma to treat emergency department patients who developed mild-to-moderate symptoms of COVID-19 because there was no evidence of efficacy. The move renewed calls for FDA to withdraw or reconsider its emergency use authorization (EUA) of convalescent plasma, raises questions about the future of large-scale expanded access programs for the therapy, and provides lessons for responding to future public health emergencies.

NIH launched the Clinical Trial of COVID-19 Convalescent Plasma of Outpatients (C3PO) in August 2020 at a time when there was a surplus of enthusiasm for the therapy and a paucity of data about its safety or efficacy. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article